ReviewGenetics in medicine : official journal of the American College of Medical Genetics2007
Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors.
Review in Genetics in medicine : official journal of the American College of Medical Genetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.Ontario health technology assessment series · 2021Pooled it
- Personalized (N-of-1) Trials for Depression: A Systematic Review.Journal of clinical psychopharmacology · 2018Pooled it
- Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.The pharmacogenomics journal · 2011Pooled it
- Application of Physiologically Based Pharmacokinetic Modeling to Optimize Assessment of Age-Related Fluoxetine Accumulation in the Elderly.CPT: pharmacometrics & systems pharmacology · 2026Article
- Ferroptosis in depression: mechanisms, association, and therapeutic strategies.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Downregulated NPAS4 in multiple brain regions is associated with major depressive disorder.Scientific reports · 2023Article
- In Silico Analyses of a Promising Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis Targeting Superoxide Dismutase I Protein.Pharmaceutics · 2023Article
- Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo.Frontiers in pharmacology · 2020Article
- Estimation of CYP3A4*1B single nucleotide polymorphism in patients with recurrent Major Depressive Disorder.Molecular genetics & genomic medicine · 2019Article
- Effects of short-term clomipramine on anxiety-like behavior, cellular metabolism, and oxidative stress in primary fibroblast cells of male and female rats.Physiological reports · 2018Article
- Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.Clinical pharmacology and therapeutics · 2014Review
- Personalized medicine in psychiatry: problems and promises.BMC medicine · 2013Review
- Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Molecular psychiatry · 2013Review
- Complex genetic architecture of Drosophila aggressive behavior.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Pharmacogenomics and personalized medicine · 2011Article
- The promise and reality of pharmacogenetics in psychiatry.The Psychiatric clinics of North America · 2010Review
- Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.CNS drugs · 2009Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
purposeCytochrome P450 (CYP450) enzymes metabolize selective serotonin reuptake inhibitor (SSRI) drugs used in treatment of depression. Variants in these genes may impact treatment efficacy and tolerability. The purpose of this study was 2-fold: to systematically review the literature for evidence supporting CYP450 genotyping to guide SSRI treatment for major depression, and, where evidence is inadequate, to suggest future research.
methodsWe searched MEDLINE(R) and other databases for studies addressing five key questions suggested by the Evaluation of Genomic Applications in Practice and Prevention Working Group. Eligibility criteria were defined, and studies were reviewed independently by paired researchers. A conceptual model was developed to guide future research.
resultsReview of 1200 abstracts led to the final inclusion of 37 articles. The evidence indicates relatively high analytic sensitivity and specificity of tests detecting a subset of polymorphisms of CYP2D6, 2C19, 2C8, 2C9, and 1A1. We found marginal evidence regarding a clinical association between CYP450 variants and SSRI metabolism, efficacy, and tolerability in the treatment of depression.
conclusionsCurrent evidence does not support the use of CYP450 genotyping to guide SSRI treatment of patients with depression. Studies are proposed that will effectively guide decision-making in the area of CYP450 testing in depression, and genetic testing more generally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.